Results 111 to 120 of about 146,874 (392)
Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment
Advanced Science, EarlyView.Soluble GRP78 (sGRP78) is identified as a novel tumor‐derived soluble factor that induces regulatory T cells (Treg). sGRP78 serves as an excellent serological biomarker for predicting the efficacy of neoadjuvant therapy in breast cancer patients. sGRP78 specifically binds to B cells, inducing the expression of IL‐10 and PD‐L1, thereby promoting Treg ...
Zhenghao Wu +10 more
wiley +1 more source
Trastuzumab in the Treatment of Breast Cancer [PDF]
BioDrugs, 2016 Breast cancer (BC) is the most common cancer in women worldwide, and has an undeniable negative impact on public health. The advent of molecular biology and immunotherapy has made targeted therapeutic interventions possible, providing treatments tailored to the individual characteristics of the patient and the disease.
Sofia Maximiano +4 more
openaire +3 more sources
Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer
Annals of Gastroenterological Surgery, EarlyView.ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda +3 more
wiley +1 more source
BMC Cancer, 2017 Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone.
Santino Minichillo +8 more
doaj +1 more source
Trastuzumab: A Cardiologist’s Perspective [PDF]
Current Oncology, 2008 A review of the randomized clinical trials of adjuvant trastuzumab in human epidermal growth factor receptor (HER2)—positive breast cancer demonstrates the great benefit of this monoclonal antibody whose potential cardiotoxicity is a fascinating problem for the cardiologist 1. [...]
openaire +3 more sources
Fluorescence Guided Surgery in Gastric Cancer: What Do We Have and What Can We Do?
Annals of Gastroenterological Surgery, EarlyView.ABSTRACT Background and Objective Fluorescence imaging has emerged as a valuable adjunct in gastric surgery, enhancing resection precision and oncologic outcomes. However, the use of indocyanine green (ICG) remains controversial due to uncertainties in efficacy and administration. A lack of standardized protocols persists.
Chun Zhuang, Han‐Kwang Yang
wiley +1 more source
Breast Cancer: Basic and Clinical Research, 2018 Purpose: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein.
John Syrios +13 more
doaj +1 more source
Breast, 2020 Objective: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1 ...
Vakaramoko Diaby +8 more
doaj +1 more source
Drugs - Real World Outcomes, 2023 Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA.
Afsaneh Barzi +6 more
doaj +1 more source
Precision oncology: the intention-to-treat analysis fallacy. [PDF]
, 2020 It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei +3 more
core +1 more source